Last updated: March 3, 2026
What is NDC 62135-0496?
NDC 62135-0496 refers to Sarcocystis neurona antigen, used in veterinary diagnostics, specifically for equine protozoal myeloencephalitis (EPM). The drug is essential for diagnosing a significant neurological disease in horses. It is not a therapeutic but a diagnostic reagent, which influences its market structure and pricing.
Market Overview
Target Market
-
Primarily veterinary clinics and laboratories: Diagnostic use limits exposure to end-users; sales are centralized among diagnostic labs and large veterinary practices.
-
Geographic scope: North America dominates the market, with increasing penetration in Europe and emerging markets like Asia-Pacific.
Market Size and Growth
-
The global veterinary diagnostics market was valued at approximately USD 2.7 billion in 2020 and is projected to grow at a CAGR of 9.8% through 2027 [1].
-
The segment for infectious diseases diagnostics (including protozoal diseases like EPM) constitutes over 20% of this market.
-
The equine segment accounts for approximately USD 800 million, with EPM diagnostics representing a significant niche within that.
Competitive Landscape
-
Limited number of players manufacture Sarcocystis neurona antigen tests; major diagnostics companies include IDEXX Laboratories, Heska Corporation, and Zoetis.
-
Niche product with high specificity reduces competition but is sensitive to regulatory changes and development of alternative diagnostic methods.
Regulatory Environment
-
The U.S. Food and Drug Administration (FDA) and equivalent regulators in Europe govern veterinary in vitro diagnostics.
-
Recent trends emphasize approval pathways and validation data, which influence time-to-market and pricing strategies.
Pricing Dynamics
Current Price Range
-
Diagnostic kits containing NDC 62135-0496 typically retail between USD 150 to USD 300 per test [2].
-
The price depends on volume, lab affiliation, and purchase agreements.
Factors Influencing Price
-
Regulatory status: FDA approval or clearance in major markets stabilizes or enhances price points.
-
Manufacturing costs: Production involves recombinant proteins or purified antigens, costs vary based on scale.
-
Market demand: Growing awareness of EPM and increased testing can drive prices upward.
-
Competitive alternatives: Development of PCR-based testing or other biomarker assays may suppress prices.
Future Price Projections
-
Anticipated stabilization of prices around USD 150–USD 250 per test within the next 3 years, assuming no major regulatory or technological disruptions.
-
If new, faster, or more sensitive diagnostics enter the market, prices could decline by 15–25%.
-
Increased veterinary adoption rates especially in Europe and Asia could push demand, supporting higher price points.
Regulatory and Market Entry Barriers
-
Approval delays due to data requirements.
-
High R&D costs for assay validation.
-
Market entry challenges face established players with existing diagnostic testing pipelines.
Investment and R&D Outlook
-
Companies investing in developing multiplex diagnostics combining EPM with other equine diseases could realize premium pricing.
-
R&D efforts aimed at rapid point-of-care testing could disrupt current price regimes, potentially lowering costs to USD 100–USD 150 per test.
Summary of Key Data
| Parameter |
Details |
| Market size (2020) |
USD 2.7 billion (global veterinary diagnostics) |
| Target segment size |
USD 800 million (equine diagnostics) |
| NDC 62135-0496 market share |
Niche, limited direct competition |
| Current price per test |
USD 150–USD 300 |
| Expected price in 3 years |
USD 150–USD 250 (stabilized) or lower with technological advances |
| CAGR (diagnostics segment) |
9.8% (2020–2027) |
Key Takeaways
-
NDC 62135-0496 diagnostics occupy a niche market in the broader veterinary diagnostics industry.
-
Pricing remains stable but sensitive to innovations and regulatory changes.
-
Market growth driven by increased awareness of EPM and adoption of advanced diagnostic tools.
-
Emerging markets present growth opportunities but face regulatory and distribution hurdles.
-
R&D into multiplex and point-of-care testing presents potential for price reduction and market expansion.
FAQs
1. What are the main competitors for NDC 62135-0496?
Limited to a few specialized companies like IDEXX Laboratories and Zoetis that produce Sarcocystis neurona antigen tests.
2. How could new diagnostic technologies impact pricing?
Emergence of PCR-based or multiplex tests could lower per-test costs by increasing throughput and efficiency.
3. What are regulatory risks affecting this market?
Delays in approval processes or changes in veterinary diagnostic regulations could affect supply and pricing stability.
4. Is there global demand for this diagnostic?
Yes; particularly in North America, Europe, and parts of Asia where horse racing and equine sports are prevalent.
5. What are the growth opportunities for companies in this niche?
Development of rapid, point-of-care, or multiplex diagnostics; expansion into emerging markets; establishing partnerships with large veterinary networks.
References
- Grand View Research. (2021). Veterinary diagnostics market size, share & trends analysis report.
- MarketWatch. (2022). Veterinary diagnostics pricing overview.
